BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/11/2022 8:36:00 AM | Browse: 554 | Download: 1164
 |
Received |
|
2021-10-30 18:28 |
|
Peer-Review Started |
|
2021-10-30 18:29 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-11-30 03:57 |
|
Revised |
|
2021-12-16 04:14 |
|
Second Decision |
|
2022-06-01 02:58 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-06-03 21:24 |
|
Articles in Press |
|
2022-06-03 21:24 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-07-02 10:46 |
|
Publish the Manuscript Online |
|
2022-07-11 08:36 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/. |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Farah Yasmin, Hala Najeeb, Unaiza Naeem, Abdul Moeed, Thoyaja Koritala and Salim Surani |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Salim Surani, FACP, FCCP, MD, MSc, Doctor, Doctor, Professor, Medicine, Texas A&M University, 400 Bizzell St, , College Station, Texas 77843, United States. srsurani@hotmail.com |
| Key Words |
Inflammatory bowel disease; Apheresis; Granulocyte–monocyte-apheresis; Leukocytapheresis; TNF-α; Ulcerative colitis; Crohn’s disease |
| Core Tip |
Granulocyte–monocyte-apheresis (GMA) and leukocytapheresis (LCAP) present as safe and viable alternatives to the conventional treatment of inflammatory bowel disease (IBD). This review summarizes the mechanism and the evidence of the efficacy of the techniques in Ulcerative Colitis (UC) and Crohn’s Disease patients. The study's key findings include a commentary on special IBD patients, the unavailability of empirical evidence of reported adverse events of GMA or LCAP in the vulnerable population, such as pregnant women. It also focuses on GMA’s unknown safety in UC patients and the barriers encountered in GMA or LCAP trials. |
| Publish Date |
2022-07-11 08:36 |
| Citation |
Yasmin F, Najeeb H, Naeem U, Moeed A, Koritala T, Surani S. Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease. World J Clin Cases 2022; 10(21): 7195-7208 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i21/7195.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i21.7195 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
